Evaluation of metronomic chemotherapy in a mouse model using DCE-MRI and DWI
Melanie Freed 1,2 , Kerryanne Winters 1,2 , Jin Zhang 1,2 , and Sungheon G. Kim 1,2
Center for Advanced Imaging Innovation and
Research (CAI2R), Dept. Radiology, NYU School of
Medicine, New York, NY, United States,
and Irene Schwartz Center for Biomedical Imaging, Dept.
Radiology, NYU School of Medicine, New York, NY, United
Metronomic chemotherapy is a promising method that
delivers chemotherapy in low, frequent doses and has
been shown to demonstrate superior response over
traditional chemotherapy in some cases. There is a need
to develop mouse models and techniques for evaluating
dose and scheduling of metronomic chemotherapy to
optimize its usage and benefits. In this study, we
investigate the use of DCE-MRI and DWI to evaluate
metronomic chemotherapy of BALB/c mice with implanted
4T1 mouse mammary tumor cells. Our data suggests this
may be a good model for advanced breast cancer and that
ADC values may be sensitive to early therapy response.
This abstract and the presentation materials are available to members only;
a login is required.